Aelis Farma: promising results in Down's syndrome

(CercleFinance.com) - Aelis Farma gained over 2% on Tuesday's trading on the Paris Bourse, following the announcement of promising results from a Phase 1/2 clinical trial in young adults with Down's Syndrome.


In a press release, the biopharmaceutical company states that the trial - which included 29 people - successfully met its objectives in terms of safety (primary endpoint), pharmacokinetics (secondary endpoint) and efficacy (secondary and exploratory endpoints).

The Bordeaux-based company adds that its drug candidate AEF0217 was well tolerated, and that no safety issues were identified.

After four weeks of treatment, AEF0217 significantly improved several important behavioral abilities in the areas of communication, daily living skills and social interaction, it explains in its press release.

For Professor Rafael de la Torre Fornell, the study's principal investigator, these improvements focused on crucial areas of adaptation, such as expressive skills.

'These types of effects, especially as they are obtained after only four weeks of treatment, are certainly a first in the field of Down's syndrome, and represent a major advance towards the development of a treatment that could significantly improve the autonomy and adaptation of people with Down's syndrome', he said.

Based on these results, Aelis Farma plans to launch an international multicenter Phase 2 dose-ranging study in Trisomy 21 patients in mid-2025.

Despite today's small rise, Aelis shares are still down 77% this year due to the failure of its Phase 2b study on AEF0117 in the treatment of cannabis abuse disorders.

Copyright (c) 2024 CercleFinance.com. All rights reserved.